Equities

Pharvaris NV

Pharvaris NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.09
  • Today's Change0.83 / 4.10%
  • Shares traded251.70k
  • 1 Year change-1.45%
  • Beta-3.1029
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments391162209
Total Receivables, Net1.040.380.70
Total Inventory------
Prepaid expenses4.964.041.51
Other current assets, total1.010.840.18
Total current assets398167212
Property, plant & equipment, net0.460.630.35
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets----0
Total assets399168212
LIABILITIES
Accounts payable2.915.982.13
Accrued expenses11114.27
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.200.190.10
Other current liabilities, total0.431.170.49
Total current liabilities15186.99
Total long term debt0.040.250.15
Total debt0.240.440.25
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities15187.14
SHAREHOLDERS EQUITY
Common stock6.274.063.98
Additional paid-in capital616289279
Retained earnings (accumulated deficit)(238)(144)(78)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.01)0.040.03
Total equity384149205
Total liabilities & shareholders' equity399168212
Total common shares outstanding523433
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.